Compare Lumen Technologies Inc (LUMN) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lumen Technologies Inc vs Neurocrine Biosciences Inc — how do they compare? Lumen Technologies Inc trades at $6.76 (market cap $6.47B), while Neurocrine Biosciences Inc trades at $179.88 (market cap $17.40B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.7× Lumen Technologies Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Lumen Technologies Inc nearer its low. Which is the better fit depends on your goals.
| LUMN | NBIX | |
|---|---|---|
Market Cap | $6.47B | $17.40B |
Sector | Media | Health |
52-Week High | $11.83 | $180.55 |
52-Week Low | $3.70 | $123.10 |
Enterprise Value | $18.10B | $16.49B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
